STOCK TITAN

[8-K] HCM II Acquisition Corp. Warrant Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Abacus Global Management, Inc. ("the Company") filed Amendment No. 1 to its Schedule TO to update documentation for its issuer tender offer and related consent solicitation covering the Company’s 20,623,395 outstanding warrants (11,723,395 public; 8,900,000 private placement).

Under the Offer, each warrant may be exchanged for 0.23 common shares (par $0.0001), implying the issuance of up to 4,743,381 new shares. Concurrently, the Company is seeking consents from at least 50 % of public-warrant holders to approve a Warrant Amendment that would allow the Company, after the offer closes, to mandatorily exchange any untendered warrants at a reduced ratio of 0.207 shares per warrant (10 % lower).

The warrants currently carry a $11.50 exercise price and trade on Nasdaq under the symbol ABLLW. By eliminating the warrants, management aims to simplify the capital structure, remove a potential overhang, and reduce future dilution that would occur if the warrants were exercised at the strike price. The filing expressly states that neither the Company nor its agents are making a recommendation to holders.

The amendment primarily replaces the prior Prospectus/Offer to Exchange and related letters originally filed on 30 June 2025 and updates Item 10 (financial statements). All other information in the original Schedule TO and incorporated Form S-4 remains unchanged.

Key considerations for investors:

  • Up to 4.74 million new shares will be issued immediately, creating direct dilution to existing common shareholders.
  • If holders do not tender and the Warrant Amendment is approved, they may be forced to accept the lower 0.207 ratio later.
  • The Company must secure consents from at least half of public-warrant holders for the amendment to become effective.
  • No cash is required; shares will be issued from authorized common stock.

The Schedule TO amendment does not modify offer economics or deadlines but refreshes the disclosure package to align with the Form S-4 amendment filed on 15 July 2025.

Abacus Global Management, Inc. ("la Società") ha presentato l'Emendamento n. 1 al suo Schedule TO per aggiornare la documentazione relativa all'offerta pubblica di acquisto di strumenti emessi e alla relativa richiesta di consenso riguardante i 20.623.395 warrant in circolazione della Società (11.723.395 pubblici; 8.900.000 in collocamento privato).

Secondo l'Offerta, ogni warrant può essere scambiato con 0,23 azioni ordinarie (valore nominale $0,0001), con l'emissione potenziale di fino a 4.743.381 nuove azioni. Contestualmente, la Società cerca il consenso di almeno il 50% dei detentori di warrant pubblici per approvare una Modifica dei Warrant che consentirebbe alla Società, dopo la chiusura dell'offerta, di scambiare obbligatoriamente i warrant non presentati a un rapporto ridotto di 0,207 azioni per warrant (10% in meno).

I warrant hanno attualmente un prezzo di esercizio di $11,50 e sono quotati al Nasdaq con il simbolo ABLLW. Eliminando i warrant, la direzione punta a semplificare la struttura del capitale, rimuovere un potenziale ostacolo e ridurre la futura diluizione che si verificherebbe se i warrant venissero esercitati al prezzo di esercizio. Nel documento si specifica chiaramente che né la Società né i suoi agenti stanno fornendo una raccomandazione ai detentori.

L'emendamento sostituisce principalmente il precedente Prospetto/Offerta di Scambio e le lettere correlate originariamente depositate il 30 giugno 2025 e aggiorna il Punto 10 (bilanci). Tutte le altre informazioni contenute nello Schedule TO originale e nel modulo S-4 incorporato restano invariate.

Considerazioni chiave per gli investitori:

  • Fino a 4,74 milioni di nuove azioni saranno emesse immediatamente, causando una diluizione diretta per gli azionisti ordinari esistenti.
  • Se i detentori non presenteranno i warrant e la Modifica dei Warrant sarà approvata, potrebbero essere obbligati ad accettare successivamente il rapporto ridotto di 0,207.
  • La Società deve ottenere il consenso di almeno la metà dei detentori di warrant pubblici affinché la modifica diventi efficace.
  • Non è richiesto denaro; le azioni saranno emesse dall'autorizzato capitale ordinario.

L'emendamento allo Schedule TO non modifica le condizioni economiche o le scadenze dell'offerta, ma aggiorna il pacchetto informativo per allinearlo all'emendamento del modulo S-4 depositato il 15 luglio 2025.

Abacus Global Management, Inc. ("la Compañía") presentó la Enmienda No. 1 a su Schedule TO para actualizar la documentación de su oferta pública de adquisición de valores emitidos y la solicitud de consentimiento relacionada que abarca los 20.623.395 warrants en circulación de la Compañía (11.723.395 públicos; 8.900.000 colocación privada).

Bajo la Oferta, cada warrant puede ser canjeado por 0,23 acciones ordinarias (valor nominal $0,0001), implicando la emisión de hasta 4.743.381 nuevas acciones. Paralelamente, la Compañía busca obtener el consentimiento de al menos el 50 % de los tenedores de warrants públicos para aprobar una Modificación de Warrants que permitiría a la Compañía, tras el cierre de la oferta, intercambiar obligatoriamente cualquier warrant no presentado a una tasa reducida de 0,207 acciones por warrant (10 % menos).

Los warrants tienen actualmente un precio de ejercicio de $11,50 y cotizan en Nasdaq bajo el símbolo ABLLW. Al eliminar los warrants, la dirección busca simplificar la estructura de capital, eliminar una posible sobrecarga y reducir la futura dilución que ocurriría si los warrants se ejercieran al precio de ejercicio. El documento aclara expresamente que ni la Compañía ni sus agentes están haciendo una recomendación a los tenedores.

La enmienda principalmente reemplaza el Prospecto/Oferta de Intercambio y cartas relacionadas presentados originalmente el 30 de junio de 2025 y actualiza el Punto 10 (estados financieros). Toda la demás información en el Schedule TO original y el Formulario S-4 incorporado permanece sin cambios.

Consideraciones clave para los inversores:

  • Se emitirán hasta 4,74 millones de nuevas acciones inmediatamente, generando una dilución directa para los accionistas ordinarios existentes.
  • Si los tenedores no presentan sus warrants y se aprueba la Modificación de Warrants, podrían verse obligados a aceptar la tasa menor de 0,207 más adelante.
  • La Compañía debe obtener el consentimiento de al menos la mitad de los tenedores de warrants públicos para que la enmienda sea efectiva.
  • No se requiere efectivo; las acciones serán emitidas del capital autorizado común.

La enmienda al Schedule TO no modifica la economía o los plazos de la oferta, sino que actualiza el paquete de divulgación para alinearlo con la enmienda del Formulario S-4 presentada el 15 de julio de 2025.

Abacus Global Management, Inc.("회사")는 발행인 공개 매수 및 관련 동의 요청과 관련된 문서를 업데이트하기 위해 Schedule TO의 수정안 1호를 제출했습니다. 이 문서는 회사의 20,623,395개의 미결제 워런트(공개 11,723,395개; 사모 8,900,000개)를 포함합니다.

제안에 따르면 각 워런트는 0.23 보통주(액면가 $0.0001)로 교환될 수 있으며, 최대 4,743,381주의 신규 주식 발행이 예상됩니다. 동시에 회사는 공개 워런트 보유자의 최소 50%로부터 동의를 얻어 워런트 수정안을 승인받으려 하며, 이 수정안이 승인되면 제안 종료 후 미제출 워런트를 강제 교환할 수 있고 교환 비율은 워런트당 0.207주(10% 감소)로 낮아집니다.

현재 워런트의 행사가격은 $11.50이며, 나스닥에서 ABLLW 심볼로 거래됩니다. 워런트를 제거함으로써 경영진은 자본 구조를 단순화하고 잠재적 부담을 제거하며, 워런트가 행사가격으로 행사될 경우 발생할 미래 희석 효과를 줄이려 합니다. 제출 문서에는 회사나 대리인이 보유자에게 권고를 하지 않는다고 명확히 명시되어 있습니다.

이번 수정안은 주로 2025년 6월 30일에 처음 제출된 이전의 투자설명서/교환 제안서 및 관련 서한을 대체하며, 항목 10(재무제표)을 업데이트합니다. 원본 Schedule TO 및 포함된 Form S-4의 다른 모든 정보는 변경되지 않았습니다.

투자자를 위한 주요 고려사항:

  • 최대 474만 주의 신규 주식이 즉시 발행되어 기존 보통주 주주에게 직접 희석 효과를 발생시킵니다.
  • 보유자가 제출하지 않고 워런트 수정안이 승인되면 이후 낮은 0.207 비율을 받아들여야 할 수 있습니다.
  • 수정안이 효력을 발휘하려면 공개 워런트 보유자의 절반 이상 동의를 얻어야 합니다.
  • 현금은 필요 없으며, 주식은 승인된 보통주에서 발행됩니다.

Schedule TO 수정안은 제안의 경제적 조건이나 기한을 변경하지 않으며, 2025년 7월 15일 제출된 Form S-4 수정안과 일치하도록 공시 자료를 갱신합니다.

Abacus Global Management, Inc. ("la Société") a déposé l'Amendement n°1 à son Schedule TO afin de mettre à jour la documentation relative à son offre publique d'achat par l'émetteur et à la sollicitation de consentement associée concernant les 20 623 395 bons de souscription en circulation de la Société (11 723 395 publics ; 8 900 000 en placement privé).

Dans le cadre de l'Offre, chaque bon peut être échangé contre 0,23 actions ordinaires (valeur nominale de 0,0001 $), impliquant l'émission pouvant atteindre 4 743 381 nouvelles actions. Parallèlement, la Société cherche à obtenir le consentement d'au moins 50 % des détenteurs de bons publics pour approuver un Amendement des Bons qui permettrait à la Société, après la clôture de l'offre, d'échanger de manière obligatoire tout bon non présenté à un ratio réduit de 0,207 action par bon (soit 10 % de moins).

Les bons ont actuellement un prix d'exercice de 11,50 $ et sont négociés sur le Nasdaq sous le symbole ABLLW. En éliminant les bons, la direction vise à simplifier la structure du capital, à éliminer un éventuel surplomb et à réduire la dilution future qui surviendrait si les bons étaient exercés au prix d'exercice. Le dépôt précise expressément que ni la Société ni ses agents ne font de recommandation aux détenteurs.

L'amendement remplace principalement le Prospectus/Offre d'Échange antérieur et les lettres associées déposés initialement le 30 juin 2025 et met à jour le point 10 (états financiers). Toutes les autres informations du Schedule TO original et du formulaire S-4 incorporé restent inchangées.

Points clés pour les investisseurs :

  • Jusqu'à 4,74 millions de nouvelles actions seront émises immédiatement, entraînant une dilution directe pour les actionnaires ordinaires existants.
  • Si les détenteurs ne présentent pas leurs bons et que l'Amendement des Bons est approuvé, ils pourraient être contraints d'accepter ultérieurement le ratio réduit de 0,207.
  • La Société doit obtenir le consentement d'au moins la moitié des détenteurs de bons publics pour que l'amendement devienne effectif.
  • Aucun paiement en espèces n'est requis ; les actions seront émises à partir du capital social autorisé.

L'amendement au Schedule TO ne modifie pas les conditions économiques ni les délais de l'offre, mais actualise le dossier d'information pour l'aligner sur l'amendement du formulaire S-4 déposé le 15 juillet 2025.

Abacus Global Management, Inc. ("das Unternehmen") hat Nachtrag Nr. 1 zu seinem Schedule TO eingereicht, um die Unterlagen für sein Emittentenübernahmeangebot und die damit verbundene Zustimmungseinholung bezüglich der 20.623.395 ausstehenden Warrants des Unternehmens (11.723.395 öffentlich; 8.900.000 Privatplatzierung) zu aktualisieren.

Im Rahmen des Angebots kann jeder Warrant gegen 0,23 Stammaktien (Nennwert $0,0001) eingetauscht werden, was die Ausgabe von bis zu 4.743.381 neuen Aktien impliziert. Gleichzeitig sucht das Unternehmen die Zustimmung von mindestens 50 % der öffentlichen Warrant-Inhaber zur Genehmigung einer Warrant-Änderung, die es dem Unternehmen nach Abschluss des Angebots ermöglichen würde, nicht eingereichte Warrants verpflichtend zu einem reduzierten Umtauschverhältnis von 0,207 Aktien pro Warrant (10 % weniger) umzutauschen.

Die Warrants haben derzeit einen Ausübungspreis von 11,50 $ und werden an der Nasdaq unter dem Symbol ABLLW gehandelt. Durch die Eliminierung der Warrants möchte das Management die Kapitalstruktur vereinfachen, einen potenziellen Überhang beseitigen und die zukünftige Verwässerung reduzieren, die auftreten würde, wenn die Warrants zum Ausübungspreis ausgeübt würden. Die Einreichung stellt ausdrücklich klar, dass weder das Unternehmen noch seine Vertreter eine Empfehlung an die Inhaber abgeben.

Die Änderung ersetzt hauptsächlich den zuvor am 30. Juni 2025 eingereichten Prospekt/das Angebot zum Umtausch und die zugehörigen Schreiben und aktualisiert Punkt 10 (Finanzberichte). Alle anderen Informationen im ursprünglichen Schedule TO und im eingegliederten Formular S-4 bleiben unverändert.

Wichtige Überlegungen für Investoren:

  • Bis zu 4,74 Millionen neue Aktien werden sofort ausgegeben, was zu einer direkten Verwässerung der bestehenden Stammaktionäre führt.
  • Wenn Inhaber nicht einreichen und die Warrant-Änderung genehmigt wird, könnten sie später gezwungen sein, das niedrigere Verhältnis von 0,207 zu akzeptieren.
  • Das Unternehmen muss die Zustimmung von mindestens der Hälfte der öffentlichen Warrant-Inhaber erhalten, damit die Änderung wirksam wird.
  • Es ist kein Bargeld erforderlich; die Aktien werden aus dem genehmigten Stammkapital ausgegeben.

Die Änderung des Schedule TO ändert weder die wirtschaftlichen Bedingungen noch die Fristen des Angebots, sondern aktualisiert das Offenlegungspaket, um mit der am 15. Juli 2025 eingereichten Änderung des Formulars S-4 übereinzustimmen.

Positive
  • Simplifies capital structure by removing up to 20.6 M warrants that could otherwise convert at $11.50.
  • Reduces future earnings dilution tied to warrant exercise, potentially improving valuation multiples.
  • No cash outlay; transaction executed with authorized shares, preserving liquidity.
Negative
  • Immediate dilution: issuance of up to 4.74 M new shares lowers existing shareholder ownership.
  • Coercive fallback ratio: untendered holders face a lower 0.207 exchange if amendment passes.
  • Approval uncertainty: 50 % public-warrant consent threshold must be met for the amendment to proceed.

Insights

TL;DR: Retiring 20.6 M warrants via 0.23-share exchange cuts overhang; 4.7 M-share dilution modestly positive overall.

The offer converts an out-of-the-money instrument (strike $11.50) into equity at a fixed 0.23 ratio, equating to roughly 2.3 shares per 10 warrants. Eliminating the warrants reduces future earnings dilution and volatility tied to warrant pricing, which can make the common stock more attractive to institutional investors. The immediate issuance of 4.74 M shares represents dilution of only the incremental difference between the current exchange and the higher potential dilution if warrants were ultimately exercised. Consequently, while near-term EPS impact is negative, the net present value could be accretive if the stock trades meaningfully below the $11.50 exercise price. Rating: modestly positive.

TL;DR: Consent solicitation gives Board power to force exchange; governance impact neutral but warrants scrutiny.

The dual-track structure—voluntary tender plus consent solicitation—offers holders choice yet pressures non-tendering investors via a 10 % worse fallback ratio. Requiring 50 % approval aligns with Warrant Agreement terms, mitigating coercion claims. Disclosures outline director and officer interests and explicitly withhold recommendations, adhering to Rule 13e-4. Governance risk appears limited, but investors should monitor participation levels and potential conflicts if insiders hold sizable warrants.

Abacus Global Management, Inc. ("la Società") ha presentato l'Emendamento n. 1 al suo Schedule TO per aggiornare la documentazione relativa all'offerta pubblica di acquisto di strumenti emessi e alla relativa richiesta di consenso riguardante i 20.623.395 warrant in circolazione della Società (11.723.395 pubblici; 8.900.000 in collocamento privato).

Secondo l'Offerta, ogni warrant può essere scambiato con 0,23 azioni ordinarie (valore nominale $0,0001), con l'emissione potenziale di fino a 4.743.381 nuove azioni. Contestualmente, la Società cerca il consenso di almeno il 50% dei detentori di warrant pubblici per approvare una Modifica dei Warrant che consentirebbe alla Società, dopo la chiusura dell'offerta, di scambiare obbligatoriamente i warrant non presentati a un rapporto ridotto di 0,207 azioni per warrant (10% in meno).

I warrant hanno attualmente un prezzo di esercizio di $11,50 e sono quotati al Nasdaq con il simbolo ABLLW. Eliminando i warrant, la direzione punta a semplificare la struttura del capitale, rimuovere un potenziale ostacolo e ridurre la futura diluizione che si verificherebbe se i warrant venissero esercitati al prezzo di esercizio. Nel documento si specifica chiaramente che né la Società né i suoi agenti stanno fornendo una raccomandazione ai detentori.

L'emendamento sostituisce principalmente il precedente Prospetto/Offerta di Scambio e le lettere correlate originariamente depositate il 30 giugno 2025 e aggiorna il Punto 10 (bilanci). Tutte le altre informazioni contenute nello Schedule TO originale e nel modulo S-4 incorporato restano invariate.

Considerazioni chiave per gli investitori:

  • Fino a 4,74 milioni di nuove azioni saranno emesse immediatamente, causando una diluizione diretta per gli azionisti ordinari esistenti.
  • Se i detentori non presenteranno i warrant e la Modifica dei Warrant sarà approvata, potrebbero essere obbligati ad accettare successivamente il rapporto ridotto di 0,207.
  • La Società deve ottenere il consenso di almeno la metà dei detentori di warrant pubblici affinché la modifica diventi efficace.
  • Non è richiesto denaro; le azioni saranno emesse dall'autorizzato capitale ordinario.

L'emendamento allo Schedule TO non modifica le condizioni economiche o le scadenze dell'offerta, ma aggiorna il pacchetto informativo per allinearlo all'emendamento del modulo S-4 depositato il 15 luglio 2025.

Abacus Global Management, Inc. ("la Compañía") presentó la Enmienda No. 1 a su Schedule TO para actualizar la documentación de su oferta pública de adquisición de valores emitidos y la solicitud de consentimiento relacionada que abarca los 20.623.395 warrants en circulación de la Compañía (11.723.395 públicos; 8.900.000 colocación privada).

Bajo la Oferta, cada warrant puede ser canjeado por 0,23 acciones ordinarias (valor nominal $0,0001), implicando la emisión de hasta 4.743.381 nuevas acciones. Paralelamente, la Compañía busca obtener el consentimiento de al menos el 50 % de los tenedores de warrants públicos para aprobar una Modificación de Warrants que permitiría a la Compañía, tras el cierre de la oferta, intercambiar obligatoriamente cualquier warrant no presentado a una tasa reducida de 0,207 acciones por warrant (10 % menos).

Los warrants tienen actualmente un precio de ejercicio de $11,50 y cotizan en Nasdaq bajo el símbolo ABLLW. Al eliminar los warrants, la dirección busca simplificar la estructura de capital, eliminar una posible sobrecarga y reducir la futura dilución que ocurriría si los warrants se ejercieran al precio de ejercicio. El documento aclara expresamente que ni la Compañía ni sus agentes están haciendo una recomendación a los tenedores.

La enmienda principalmente reemplaza el Prospecto/Oferta de Intercambio y cartas relacionadas presentados originalmente el 30 de junio de 2025 y actualiza el Punto 10 (estados financieros). Toda la demás información en el Schedule TO original y el Formulario S-4 incorporado permanece sin cambios.

Consideraciones clave para los inversores:

  • Se emitirán hasta 4,74 millones de nuevas acciones inmediatamente, generando una dilución directa para los accionistas ordinarios existentes.
  • Si los tenedores no presentan sus warrants y se aprueba la Modificación de Warrants, podrían verse obligados a aceptar la tasa menor de 0,207 más adelante.
  • La Compañía debe obtener el consentimiento de al menos la mitad de los tenedores de warrants públicos para que la enmienda sea efectiva.
  • No se requiere efectivo; las acciones serán emitidas del capital autorizado común.

La enmienda al Schedule TO no modifica la economía o los plazos de la oferta, sino que actualiza el paquete de divulgación para alinearlo con la enmienda del Formulario S-4 presentada el 15 de julio de 2025.

Abacus Global Management, Inc.("회사")는 발행인 공개 매수 및 관련 동의 요청과 관련된 문서를 업데이트하기 위해 Schedule TO의 수정안 1호를 제출했습니다. 이 문서는 회사의 20,623,395개의 미결제 워런트(공개 11,723,395개; 사모 8,900,000개)를 포함합니다.

제안에 따르면 각 워런트는 0.23 보통주(액면가 $0.0001)로 교환될 수 있으며, 최대 4,743,381주의 신규 주식 발행이 예상됩니다. 동시에 회사는 공개 워런트 보유자의 최소 50%로부터 동의를 얻어 워런트 수정안을 승인받으려 하며, 이 수정안이 승인되면 제안 종료 후 미제출 워런트를 강제 교환할 수 있고 교환 비율은 워런트당 0.207주(10% 감소)로 낮아집니다.

현재 워런트의 행사가격은 $11.50이며, 나스닥에서 ABLLW 심볼로 거래됩니다. 워런트를 제거함으로써 경영진은 자본 구조를 단순화하고 잠재적 부담을 제거하며, 워런트가 행사가격으로 행사될 경우 발생할 미래 희석 효과를 줄이려 합니다. 제출 문서에는 회사나 대리인이 보유자에게 권고를 하지 않는다고 명확히 명시되어 있습니다.

이번 수정안은 주로 2025년 6월 30일에 처음 제출된 이전의 투자설명서/교환 제안서 및 관련 서한을 대체하며, 항목 10(재무제표)을 업데이트합니다. 원본 Schedule TO 및 포함된 Form S-4의 다른 모든 정보는 변경되지 않았습니다.

투자자를 위한 주요 고려사항:

  • 최대 474만 주의 신규 주식이 즉시 발행되어 기존 보통주 주주에게 직접 희석 효과를 발생시킵니다.
  • 보유자가 제출하지 않고 워런트 수정안이 승인되면 이후 낮은 0.207 비율을 받아들여야 할 수 있습니다.
  • 수정안이 효력을 발휘하려면 공개 워런트 보유자의 절반 이상 동의를 얻어야 합니다.
  • 현금은 필요 없으며, 주식은 승인된 보통주에서 발행됩니다.

Schedule TO 수정안은 제안의 경제적 조건이나 기한을 변경하지 않으며, 2025년 7월 15일 제출된 Form S-4 수정안과 일치하도록 공시 자료를 갱신합니다.

Abacus Global Management, Inc. ("la Société") a déposé l'Amendement n°1 à son Schedule TO afin de mettre à jour la documentation relative à son offre publique d'achat par l'émetteur et à la sollicitation de consentement associée concernant les 20 623 395 bons de souscription en circulation de la Société (11 723 395 publics ; 8 900 000 en placement privé).

Dans le cadre de l'Offre, chaque bon peut être échangé contre 0,23 actions ordinaires (valeur nominale de 0,0001 $), impliquant l'émission pouvant atteindre 4 743 381 nouvelles actions. Parallèlement, la Société cherche à obtenir le consentement d'au moins 50 % des détenteurs de bons publics pour approuver un Amendement des Bons qui permettrait à la Société, après la clôture de l'offre, d'échanger de manière obligatoire tout bon non présenté à un ratio réduit de 0,207 action par bon (soit 10 % de moins).

Les bons ont actuellement un prix d'exercice de 11,50 $ et sont négociés sur le Nasdaq sous le symbole ABLLW. En éliminant les bons, la direction vise à simplifier la structure du capital, à éliminer un éventuel surplomb et à réduire la dilution future qui surviendrait si les bons étaient exercés au prix d'exercice. Le dépôt précise expressément que ni la Société ni ses agents ne font de recommandation aux détenteurs.

L'amendement remplace principalement le Prospectus/Offre d'Échange antérieur et les lettres associées déposés initialement le 30 juin 2025 et met à jour le point 10 (états financiers). Toutes les autres informations du Schedule TO original et du formulaire S-4 incorporé restent inchangées.

Points clés pour les investisseurs :

  • Jusqu'à 4,74 millions de nouvelles actions seront émises immédiatement, entraînant une dilution directe pour les actionnaires ordinaires existants.
  • Si les détenteurs ne présentent pas leurs bons et que l'Amendement des Bons est approuvé, ils pourraient être contraints d'accepter ultérieurement le ratio réduit de 0,207.
  • La Société doit obtenir le consentement d'au moins la moitié des détenteurs de bons publics pour que l'amendement devienne effectif.
  • Aucun paiement en espèces n'est requis ; les actions seront émises à partir du capital social autorisé.

L'amendement au Schedule TO ne modifie pas les conditions économiques ni les délais de l'offre, mais actualise le dossier d'information pour l'aligner sur l'amendement du formulaire S-4 déposé le 15 juillet 2025.

Abacus Global Management, Inc. ("das Unternehmen") hat Nachtrag Nr. 1 zu seinem Schedule TO eingereicht, um die Unterlagen für sein Emittentenübernahmeangebot und die damit verbundene Zustimmungseinholung bezüglich der 20.623.395 ausstehenden Warrants des Unternehmens (11.723.395 öffentlich; 8.900.000 Privatplatzierung) zu aktualisieren.

Im Rahmen des Angebots kann jeder Warrant gegen 0,23 Stammaktien (Nennwert $0,0001) eingetauscht werden, was die Ausgabe von bis zu 4.743.381 neuen Aktien impliziert. Gleichzeitig sucht das Unternehmen die Zustimmung von mindestens 50 % der öffentlichen Warrant-Inhaber zur Genehmigung einer Warrant-Änderung, die es dem Unternehmen nach Abschluss des Angebots ermöglichen würde, nicht eingereichte Warrants verpflichtend zu einem reduzierten Umtauschverhältnis von 0,207 Aktien pro Warrant (10 % weniger) umzutauschen.

Die Warrants haben derzeit einen Ausübungspreis von 11,50 $ und werden an der Nasdaq unter dem Symbol ABLLW gehandelt. Durch die Eliminierung der Warrants möchte das Management die Kapitalstruktur vereinfachen, einen potenziellen Überhang beseitigen und die zukünftige Verwässerung reduzieren, die auftreten würde, wenn die Warrants zum Ausübungspreis ausgeübt würden. Die Einreichung stellt ausdrücklich klar, dass weder das Unternehmen noch seine Vertreter eine Empfehlung an die Inhaber abgeben.

Die Änderung ersetzt hauptsächlich den zuvor am 30. Juni 2025 eingereichten Prospekt/das Angebot zum Umtausch und die zugehörigen Schreiben und aktualisiert Punkt 10 (Finanzberichte). Alle anderen Informationen im ursprünglichen Schedule TO und im eingegliederten Formular S-4 bleiben unverändert.

Wichtige Überlegungen für Investoren:

  • Bis zu 4,74 Millionen neue Aktien werden sofort ausgegeben, was zu einer direkten Verwässerung der bestehenden Stammaktionäre führt.
  • Wenn Inhaber nicht einreichen und die Warrant-Änderung genehmigt wird, könnten sie später gezwungen sein, das niedrigere Verhältnis von 0,207 zu akzeptieren.
  • Das Unternehmen muss die Zustimmung von mindestens der Hälfte der öffentlichen Warrant-Inhaber erhalten, damit die Änderung wirksam wird.
  • Es ist kein Bargeld erforderlich; die Aktien werden aus dem genehmigten Stammkapital ausgegeben.

Die Änderung des Schedule TO ändert weder die wirtschaftlichen Bedingungen noch die Fristen des Angebots, sondern aktualisiert das Offenlegungspaket, um mit der am 15. Juli 2025 eingereichten Änderung des Formulars S-4 übereinzustimmen.

false 0002019804 0002019804 2025-07-15 2025-07-15 0002019804 HOND:UnitsEachConsistingOfOneShareOfClassOrdinaryShareAndOnehalfOfOneRedeemableWarrantMember 2025-07-15 2025-07-15 0002019804 HOND:ClassOrdinarySharesParValue0.0001PerShareMember 2025-07-15 2025-07-15 0002019804 HOND:RedeemableWarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtPriceOf11.50PerShareMember 2025-07-15 2025-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): July 15, 2025

 

HCM II Acquisition Corp.

(Exact name of registrant as specified in its charter)

 

Cayman Islands   001-42252   98-1785406
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

100 First Stamford Place, Suite 330

Stamford, CT 06902

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (203) 930-2200

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading Symbol(s)

 

Name of each exchange on

which registered

Units, each consisting of one share of Class A ordinary share and one-half of one Redeemable Warrant   HONDU   The Nasdaq Stock Market LLC
Class A ordinary shares, par value $0.0001 per share   HOND   The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at a price of $11.50 per share   HONDW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

 

On July 15, 2024, the audit committee of the board of directors of HCM II Acquisition Corp. (the “Company”) concluded that the Company’s previously issued (i) consolidated financial statements as of and for the year ended December 31, 2024 included in its Annual Report on Form 10-K for the year ended December 31, 2024 (“Annual Period”), and (ii) unaudited condensed consolidated financial statements for the quarter ended March 31, 2025 included in its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (“Current Interim Period”) should no longer be relied upon due to an error in the related party transaction disclosure in Footnote 5 incorrectly stating that the underwriter in the Company’s initial public offering was a related party of the Company.

 

The Company intends to restate the consolidated financial statements of the Annual Period (the “10-K Restatement”) in its Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K/A”), as soon as reasonably practicable. Additionally, the Company intends to restate the consolidated financial statements of the Current Interim Period (the “10-Q Restatement”) in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (the “2025 Form 10-Q/A”), as soon as reasonably practicable.

 

The Company’s management and the Audit Committee discussed the matters disclosed in this Item 4.02 with WithumSmith+Brown, PC, the Company’s independent accounting registered public firm. At this time, the Company does not have an estimate of when all efforts will be completed and when the 2024 Form 10-K/A and 2025 Form 10-Q/A will be filed.

 

Forward-Looking Statements

 

This report may contain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation: statements related to the completion of the Company’s review of accounting matters and audit of the Company’s financial statements; the Company’s plans to file the 2025 Form 10-Q/A and 2024 Form 10-K/A with the restated results; expectations with respect to how the adjustments will impact the Company’s financial statements; and the Company’s plans, objectives and intentions that are not historical facts generally. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by the forward-looking statement, including without limitation: the final outcome of the evaluation of accounting matters and the impact of the adjustments to the Company’s financial statements; the discovery of additional and unanticipated information during the re-evaluation and audit of the Company’s financial statements, including it evaluation of effectiveness of internal control over financial reporting; changes in assumptions regarding how the evaluation will impact the Company’s financial results; the application of accounting or tax principles in an unanticipated manner; the possibility that the Nasdaq may delist the Company’s securities; risks related to the Company’s ability to implement and maintain effective internal control over financial reporting in the future; and the impact of these factors on the Company’s performance and outlook. See also other risks that are described in “Risk Factors” in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC for the fiscal year ended December 31, 2024, and any subsequent reports filed with the SEC. All forward-looking statements in this report are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  HCM II ACQUISITION CORP.
     
  By: /s/ Shawn Matthews
  Name:  Shawn Matthews
  Title: Chief Executive Officer
     
Date: July 15, 2025    

 

 

2

 

FAQ

What is Abacus Global Management (ABLLW) offering to warrant holders?

Holders may exchange each warrant for 0.23 common shares under the tender offer.

How many warrants and shares are involved in the exchange?

The offer covers 20,623,395 warrants and would issue up to 4,743,381 common shares.

What happens if the Warrant Amendment is approved?

Any warrants outstanding after the offer could be forcibly exchanged at 0.207 shares per warrant, a 10 % lower ratio.

What level of consent is needed to adopt the Warrant Amendment?

50 % of the outstanding public warrants must consent for the amendment to become effective.

Does Abacus recommend that holders tender their warrants?

No. The filing states that neither the Company nor its agents make any recommendation regarding tendering.
HCM II Acquisition Corp

NASDAQ:HONDW

HONDW Rankings

HONDW Latest News

HONDW Latest SEC Filings

HONDW Stock Data

11.50M
Blank Checks
STAMFORD